|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome显示文摘Cytokine release syndrome(CRS)is a major obstacle to the widespread clinical application of chimeric antigen receptor(CAR)T cell therapies.CRS can also be induced by infections(such as SARS-CoV-2),drugs(such as therapeutic antibodies),and some autoimmune diseases.Myeloid-derived macrophages play key roles in the pathogenesis of CRS,and participate in the production and release of the core CRS cytokines,including interleukin(IL)-1,IL-6,and interferon-γ.In this review,we summarize the roles of macrophages in CRS and discuss new developments in macrophage activation and the related mechanisms of cytokine regulation in CRS. | Hanfei Guo Lei Qian Jiuwei Cui | 2022 | Cancer Biology & Medicine2022，19，3： | 6 |
| 2 | Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer显示文摘Immune checkpoint inhibitors(ICIs),a type of immunotherapy,have become one of the most important therapeutic options for first-and second-line treatment of advanced non-small cell lung cancer(NSCLC).Recent clinical studies have shown that immunotherapy can offer substantial survival benefits to patients with early-stage or resectable advanced NSCLC.However,considering the importance of timing when using ICIs and their associated adverse events(AEs),the advantages and disadvantages of using these agents need to be weighed carefully when deciding the use of a combined treatment.In addition,the inconsistency between imaging assessment and pathological results poses further challenges to the evaluation of efficacy of neoadjuvant immunotherapy.It is also important to develop new methodologies and discover suitable biomarkers that can be used to evaluate survival outcomes of immunotherapy and identify patients who would benefit the most from this treatment.In this review,we aimed to summarize previous results of ongoing clinical trials on neoadjuvant immunotherapy for lung cancer and discuss the challenges and future perspectives of this therapeutic approach in the treatment of resectable NSCLC. | Hanfei Guo Wenqian Li Lei Qian Jiuwei Cui | 2021 | Chinese Journal of Cancer Research2021，33，2： | 5 |
| 3 | MRD-directed and risk-adapted individualized stratified treatment of AML显示文摘Measurable residual disease(MRD)has been widely recognized as a biomarker for deeply evaluating complete remission(CR),predicting relapse,guiding pre-emptive interventions,and serving as an endpoint surrogate for drug testing.However,despite the emergence of new technologies,there remains a lack of comprehensive understanding regarding the proper techniques,sample materials,and optimal time points for MRD assessment.In this review,we summarized the MRD methods,sample sources,and evaluation frequency according to the risk category of the European Leukemia Net(ELN)2022.Additionally,we emphasize the importance of properly utilizing and combining these technologies.We have also refined the flowchart outlining each time point for preemptive interventions and intervention paths.The evaluation of MRD in acute myeloid leukemia(AML)is sophisticated,clinically applicable,and technology-dependent,and necessitates standardized approaches and further research. | Yijing Zhao Hanfei Guo Yingjun Chang | 2023 | Chinese Journal of Cancer Research2023，35，5： | 0 |
| 4 | Coexisting opportunities and challenges:In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?显示文摘Curative therapy was not previously available for patients with advanced non-small cell lung cancer(NSCLC);thus,the concept of minimal/measurable(or molecular)residual disease(MRD)was not applicable to these patients.However,advances in targeted and immunotherapy have revolutionized the treatment landscape for patients with advanced NSCLC,with emerging evidence of long-term survival and even the hope of complete remission(CR)by imaging examination.The latest research shows that patients with oligometastatic lung cancer can benefit from local treatment.After removing the lesions,the choice of follow-up therapy and monitoring of the lesions could remain uncertain.MRD plays a role in identifying early-stage NSCLC patients with high risks of recurrence and determining adjuvant therapy after radical treatment.In recent years,evidence has been accumulating regarding the use of circulating cell-free tumor DNA(ctDNA)to assess MRD in solid tumors.This study discussed the possible applications of ctDNA-based MRD monitoring in advanced NSCLC and described the current challenges and unresolved problems in the application of MRD in advanced NSCLC. | Hanfei Guo Wenqian Li Bin Wang Neifei Chen Lei Qian Jiuwei Cui | 2021 | Chinese Journal of Cancer Research2021，33，5： | 0 |
| 5 | Review of intelligent diagnosis methods for imaging gland cancer based on machine learning显示文摘Gland cancer is a high-incidence disease that endangers human health,and its early detection and treatment require efficient,accurate,and objective intelligent diagnosis methods.In recent years,the advent of machine learning techniques has yielded satisfactory results in intelligent gland cancer diagnosis based on clinical images,significantly improving the accuracy and efficiency of medical image interpretation while reducing the workload of doctors.The focus of this study is to review,classify,and analyze intelligent diagnosis methods for imaging gland cancer based on machine learning and deep learning.This paper briefly introduces some basic imaging principles of multimodal medical images,such as the commonly used computed tomography(CT),magnetic resonance imaging(MRI),ultrasound(US),positron emission tomography(PET),and pathology.In addition,the intelligent diagnosis methods for imaging gland cancer were further classified into supervised learning and weakly supervised learning.Supervised learning consists of traditional machine learning methods,such as K-nearest neighbor algorithm(KNN),support vector machine(SVM),and multilayer perceptron,and deep learning methods evolving from convolutional neural network(CNN).By contrast,weakly supervised learning can be further categorized into active learning,semisupervised learning,and transfer learning.State-of-the-art methods are illustrated with implementation details,including image segmentation,feature extraction,and optimization of classifiers.Their performances are evaluated through indicators,such as accuracy,precision,and sensitivity.In conclusion,the challenges and development trends of intelligent diagnosis methods for imaging gland cancer were addressed and discussed. | Han JIANG Wenjia SUN Hanfei GUO Jiayuan ZENG Xin XUE Shuai LI | 2023 | Virtual Reality & Intelligent Hardware2023，5，4： | 0 |
| 6 | Reversible phase transition for switchable second harmonic generation in 2D perovskite microwires显示文摘Highly efficient second-harmonic generation(SHG)has facilitated the development of nanophotonics and sustained promising applications,ranging from electro-optical modulation,frequency conversion,and optical frequency combs to pulse characterization.Although controllable SHG switching has been observed in nanophotonics structures and molecule systems,the relatively small SHG switching contrast impedes its application in switchable nonlinear optics.Herein,reversible phase transitions between glassy and crystalline states without material degradation are demonstrated based on solution-processed chiral perovskite microwire arrays.Breaking of lattice inversion symmetry and high crystallinity support efficient SHG in microwire arrays.By synergy of high-performance SHG and reversible phase transitions between glassy and crystalline states,reversible switching of SHG is demonstrated under facile conditions.The high SHG switching performances,together with a small footprint,pave the way toward the integration of switchable nonlinear devices based on microwire arrays. | Yingjie Zhao Jiahui Zhao Yangwu Guo Jinjin Zhao Jiangang Feng Yue Geng Junchuan Yang Hanfei Gao Meng Yuan Lei Jiang Yuchen Wu | 2022 | SmartMat2022，3，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员